Iwona Buczynska
Wroclaw, DS 50149, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Liver Injury in Patients with COVID-19 without Underlying Liver Disease.
Journal: Journal of clinical medicine
Published: December 01, 2021
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Journal: World journal of gastroenterology
Published: January 26, 2021
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Journal: Journal of gastroenterology and hepatology
Published: September 10, 2020
Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: August 30, 2020
Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.
Journal: Expert review of anti-infective therapy
Published: June 16, 2020
Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection.
Journal: Polish archives of internal medicine
Published: April 07, 2020
Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.
Journal: Polish archives of internal medicine
Published: February 08, 2020
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Journal: Journal of gastroenterology and hepatology
Published: September 05, 2019
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Journal: Advances in medical sciences
Published: February 09, 2019
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting.
Journal: Archives of medical science : AMS
Published: January 23, 2019
Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
Journal: Canadian journal of gastroenterology & hepatology
Published: December 09, 2018
Last Updated: 09/26/2026